President Trump on Wednesday signed the U.S.-Mexico-Canada trade agreement (USMCA), a renegotiated version of the North American Free Trade Agreement (NAFTA) that includes new rules on patent protections for pharmaceuticals and excludes a 10-year exclusivity period for biologic drugs.
Your cheat sheets for understanding health care's legal landscape
While the Trump administration has approved the deal, it's not in effect just yet. Mexico has ratified the deal, but it still needs approval from Canada. Canada is expected to ratify the agreement in a few weeks, meaning the rules will go into effect in a few months, according to the Wall Street Journal.
The USMCA would update NAFTA for the first time in more than two decades. The agreement includes several provisions that would affect the health care industry.
For instance, regarding drug pricing the final version of the deal does not include a provision in an earlier iteration of the deal that would grant a 10-year exclusivity period for biologics.
When President Trump in 2018 announced a version of the agreement, initially included a provision to offer 10 years of exclusivity for biologics—such as injected drugs used to treat cancer and immune disorders—in Canada, Mexico, and the United States.
However, the provision was ultimately dropped in a deal between the Trump administration and Democratic lawmakers who said it would not do enough to address concerns about drug prices. Drugmakers currently receive 12 years of exclusivity in the United States for biologic drugs, while drugmakers receive eight years of in Canada. In Mexico, drugmakers receive five years of exclusivity for their products, but Mexico's regulations do not explicitly state whether the five-year exclusivity period applies to biologic drugs.
Further, the approved version of the USMCA also excludes provisions that were included in the 2018 version of the deal that would have required the United States, Canada, and Mexico to:
In addition, under lawmakers' December 2019 agreement with the administration, they revised a:
Moreover, the agreement would expand protections for other intellectual property rights, according to the New York Times. The new deal, for instance would extend protection for copyrights from 50 years to 70 years. The measure also includes new criminal penalties for theft of trade secret.
According to the Journal, some big drugmakers are disappointed that the deal won't include the 10-year exclusivity period that would protect biologics from generic competition in Mexico and Canada. According to Associated Press, drugmakers argued that biologics manufacturers need years of protection to profit from their drugs before generic competition is introduced, saying that drug companies that rely on money from venture capital firms would not be incentivized to invest in developing new drugs.
Pharmaceutical Research and Manufacturers of America in a statement last year said, "Eliminating the biologics provision in the USMCA removes vital protections for innovators while doing nothing to help U.S. patients afford their medicines or access future treatments and cures."
Separately, U.S. Trade Representative Robert Lighthizer when the updated deal was announced last year said, "Clearly, getting rid of the biologic provision was a step backwards…that was a compromise" (Wiseman, Associated Press, 12/19/19; Lawder et al., Reuters, 1/29; Swanson/Tankersley, New York Times, 1/29; Mauldin/Leary, Wall Street Journal, 1/29).
Create your free account to access 2 resources each month, including the latest research and webinars.
You have 2 free members-only resources remaining this month remaining this month.
Never miss out on the latest innovative health care content tailored to you.